| 2026 |
From asthma theory to practice: insights from real life |
Lettera |
Vai |
| 2026 |
Ex vivo air–liquid interface respiratory mucosa platform to study type 2–driven asthma |
Articolo in rivista |
Vai |
| 2025 |
Current status of biological therapy use for older adults with severe asthma |
Review essay (rassegna critica) |
Vai |
| 2025 |
A novel approach to investigate severe asthma and COPD: the 3d ex vivo respiratory mucosa model |
Articolo in rivista |
Vai |
| 2025 |
Exploring a novel approach to COPD treatment: benralizumab effect in an ex vivo 3-D model |
Articolo in rivista |
Vai |
| 2025 |
The effects of benralizumab on lung volume changes during exercise in experimental setting in severe asthmatics: a pilot study |
Articolo in rivista |
Vai |
| 2025 |
The multidisciplinary team reduces the time to idiopathic pulmonary fibrosis diagnosis in a real-life setting |
Articolo in rivista |
Vai |
| 2024 |
Triple inhaled therapy in asthma: Beliefs, behaviours and doubts |
Articolo in rivista |
Vai |
| 2024 |
Are nighttime respiratory symptoms assessed by asthma control test affected by comorbidities? |
Articolo in rivista |
Vai |
| 2024 |
Patients with bronchiectasis have a lower combined risk of cardiovascular risk factors and cardiovascular comorbidity compared to patients with COPD |
Articolo in rivista |
Vai |
| 2024 |
Ascending aortic thrombosis in COVID respiratory patient: the “perfect storm” |
Articolo in rivista |
Vai |
| 2023 |
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study |
Articolo in rivista |
Vai |
| 2023 |
Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis |
Articolo in rivista |
Vai |
